What’s Next at #ESMO22 | Amgen

What’s Next at #ESMO22

The largest and broadest global KRASG12C inhibitor development program is progressing to help more patients.

The European Society for Medical Oncology Congress 2022 (ESMO) has officially kicked off in Paris. Each year, ESMO convenes some of the world's most influential oncology experts to discuss the latest advances in cancer care.

What's Next at ESMO 2022

Key data from Amgen's global KRASG12C inhibitor development program will be presented at ESMO, including detailed confirmatory data from the first randomized, controlled Phase 3 clinical trial of a KRASG12C inhibitor in non-small cell lung cancer.

New combination data from the CodeBreaK 101 study in patients with KRAS G12C-mutated colorectal cancer (CRC) will also be presented. KRAS is a commonly mutated oncogene in CRC, with mutations in approximately 40% of all cases, with the KRAS G12C mutation present in approximately 3-5% of colorectal cancers. These patients have a dismal prognosis and have very limited treatment options.

Optimizing Biomarker Testing

A critical component to KRAS treatment remains optimizing biomarker testing for patients. Leading up to ESMO, Amgen leaders Jean-Charles Soria, senior vice president and head of Amgen's Oncology Therapeutic Area, I-Fen Chang, vice president of Oncology Late Development, and David Raben, vice president of Oncology Global Development, spoke with special guest Dr. Kashyap Patel, president of the Community Oncology Alliance, to discuss new innovations in thoracic oncology.

The group also talked about Amgen's work in collaboration with organizations like the Community Oncology Alliance to expand biomarker testing and ensure results are leveraged to inform treatment throughout a patient's journey.

Listen to the full Twitter Spaces conversation below.


Be sure to follow Amgen Oncology on Twitter for real-time updates throughout ESMO, and follow the event hashtag on Twitter #ESMO22 for the latest congress news.

Share This Story